Viral hepatitis. From prevention to antivirals.
The challenge of viral hepatitis has been acknowledged and confronted in the last decade. Significant progress in prevention of infection with HAV and HBV may eradicate these serious infections from the United States and other parts of the world in the coming decades. Application of prophylactic strategies to children will be a major mechanism in accomplishing this task. The quest for potent antiviral medications continues. The next critically important development will be ways to prevent new HCV infections and to treat the millions of already infected individuals at risk for the serious consequences of this disease. For pediatricians, realizing these goals requires a greater understanding of perinatal HCV transmission, use of vaccines for prevention of viral hepatitis, and identification of HCV-infected children who are likely to benefit from new therapeutic strategies as they become available.
Jonas
M M
MM
Department of Pediatrics, Harvard Medical School, and the Division of Gastroenterology, Children's Hospital, Boston, Massachusetts, USA. jonas@hub.tch.harvard.edu
D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006506:Hepatitis A / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control / Q000821:virology; D006509:Hepatitis B / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control / Q000821:virology; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control / Q000821:virology; D006525:Hepatitis, Viral, Human / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D007231:Infant, Newborn; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use
D000998:Antiviral Agents; D014761:Viral Hepatitis Vaccines